Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reference drug programs: effectiveness and policy implications.

Sebastian Schneeweiss1

  • 1Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA. schnee@post.harvard.edu

Health Policy (Amsterdam, Netherlands)
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data.

BMJ medicine·2024
Same author

Hypothetical Assessments of Trial Emulations.

JAMA internal medicine·2024
Same author

Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center.

BMJ (Clinical research ed.)·2024
Same author

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.

Cardiovascular diabetology·2024
Same author

Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases.

JAMA dermatology·2024
Same author

Proceedings of the International Ambulatory Drug Safety Symposium: Munich, Germany, June 2023.

Drug safety·2023
Same journal

Basic human values, responsiveness, and dignity in geriatric organizations in Israel: A qualitative study of state regulations.

Health policy (Amsterdam, Netherlands)·2026
Same journal

A policy analysis of the three-month waiting period for new and returning residents to access provincial health insurance in Ontario, Canada.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Policy priorities in palliative and end-of-life care: An exploration of issues reflected in public strategy.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Advancing stakeholder analysis: Power and participation in health technology assessment policy development in the United Arab Emirates.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Cultural sensitivity concerning the Gaeltacht people of Ireland - a concept analysis.

Health policy (Amsterdam, Netherlands)·2026
Same journal

Israel's 2010 capitation reform and the widening of regional health disparities: A difference-in-differences analysis.

Health policy (Amsterdam, Netherlands)·2026
See all related articles

Reference drug programs (RDPs) control rising drug costs by reimbursing therapeutically equivalent medications at a common level, ensuring cost-effectiveness and patient access. These programs offer a safe and efficient approach to managing pharmaceutical spending.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Pharmacoeconomics

Background:

  • Healthcare systems face escalating costs, with drug expenditures being a primary concern.
  • Reference drug programs (RDPs) are increasingly adopted to manage pharmaceutical spending.
  • These programs assume therapeutic equivalence among drugs within defined classes for reimbursement.

Purpose of the Study:

  • To elucidate the mechanism and rationale behind Reference Drug Programs (RDPs).
  • To present evidence on the economic effectiveness and clinical safety of RDPs.
  • To discuss the implications of implementing RDP policies in healthcare.

Main Methods:

  • Review of existing literature on Reference Drug Programs (RDPs).
  • Analysis of economic and clinical data related to therapeutic substitution.

Related Experiment Videos

  • Examination of RDPs as an extension of generic substitution policies.

    • Main Results:

    • RDPs establish a common reimbursement level for therapeutically equivalent drugs.
    • Evidence supports the economic effectiveness and clinical safety of RDPs.
    • RDPs, combined with prior authorization, are more effective than simplistic cost-sharing measures.

    Conclusions:

    • RDPs reduce spending on less innovative drugs while ensuring patient coverage.
    • Prior authorization ensures access to innovative therapies for specific indications.
    • Medically indicated exemptions are crucial for comprehensive RDP implementation.